{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:02:42Z","timestamp":1785164562507,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We describe a patient with long-standing rheumatoid arthritis (RA) who developed severe refractory transfusion-dependent anaemia lasting several months following treatment with a JAK1 inhibitor (Filgotinib). The patient proceeded with extensive investigations, including bone marrow assessment, and was initially diagnosed with Filgotinib-associated anaemia. However, despite stopping this agent, the anaemia persisted with fluctuating reticulocyte count resulting in multiple hospital admissions. Although the anaemia was initially attributed to Filgotinib, its persistence alongside delayed reticulocytopenia, ultimately led to a diagnosis of acquired Pure Red Cell Aplasia more than 12\u00a0months later. Complete remission was achieved with prednisolone + ciclosporin A. This case underscores the need to consider PRCA in RA patients on JAK inhibitors even with initially normal reticulocyte counts, as these agents may transiently mask underlying aplasia.<\/jats:p>","DOI":"10.1093\/omcr\/omag125","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:44:25Z","timestamp":1783896265000},"source":"Crossref","is-referenced-by-count":0,"title":["Pure red cell aplasia in a patient with rheumatoid arthritis after JAK inhibitor exposure\u2014diagnostic challenges"],"prefix":"10.1093","volume":"2026","author":[{"given":"Shashi","family":"Rajnarinesingh","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy\u2019s Hospital , London SE1 9RT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Georgiou","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s Hospital , London SE1 9RT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Prasannan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s Hospital , London SE1 9RT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8909","authenticated-orcid":false,"given":"Priya","family":"Sriskandarajah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s Hospital , London SE1 9RT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"2026072710484489300_ref1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1055\/s-0042-1757584","article-title":"Pure red cell aplasia encountered in a tertiary care Hematology laboratory: a series of nine distinctive cases","volume":"15","author":"Kala","year":"2022","journal-title":"J Lab Physicians"},{"key":"2026072710484489300_ref2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.amjms.2023.06.009","article-title":"Pure red cell aplasia: the second hundred years","volume":"366","author":"Means","year":"2023","journal-title":"Am J Med Sci"},{"key":"2026072710484489300_ref3","doi-asserted-by":"publisher","first-page":"ii49","DOI":"10.1093\/rheumatology\/kex062","article-title":"Case reports 001. Pure red cell aplasia: a rare and challenging extra-articular manifestation of rheumatoid arthritis","volume":"56","author":"Kuang","year":"2017","journal-title":"Rheumatology"},{"key":"2026072710484489300_ref4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.55563\/clinexprheumatol\/166dsf","article-title":"Novel insights into the management of rheumatoid arthritis: one year in review 2024","volume":"42","author":"Molteni","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026072710484489300_ref5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026072710484489300_ref6","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2023-eular.1076","article-title":"AB0492 Anemia in patients with rheumatoid arthritis treated with jak inhibitors","volume":"82","author":"Takeuchi","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026072710484489300_ref7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40261-021-01055-0","article-title":"Filgotinib in rheumatoid arthritis: a profile of its use","volume":"41","author":"Kim","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2026072710484489300_ref8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/j.1537-2995.2008.01749.x","article-title":"Epoetin-associated pure red cell aplasia: past, present, and future considerations","volume":"48","author":"McKoy","year":"2008","journal-title":"Transfusion."},{"key":"2026072710484489300_ref9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2141.1986.tb07495.x","article-title":"Pure red cell aplasia: lymphocyte inhibition of erythropoiesis","volume":"63","author":"Abkowitz","year":"1986","journal-title":"Br J Haematol"},{"key":"2026072710484489300_ref10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3324\/haematol.11192","article-title":"PRCA collaborative study group. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine a. a nationwide cohort study in Japan for the PRCA collaborative study group","volume":"92","author":"Sawada","year":"2007","journal-title":"Haematologica."}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/7\/omag125\/68760959\/omag125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/7\/omag125\/68760959\/omag125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:48:55Z","timestamp":1785163735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omag125\/8732784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omag125","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"omag125"}}